Cynthia Hawkins

Cynthia Hawkins

Auto-generated profile, based on publicly available information

Cynthia Hawkins

Division of Pathology, The Hospital for Sick Children, Toronto, Canada

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2003
Verified
Journal Article
Closed access
Sheila SinghSheila Singh
Sheila Singh
ICIan D Clarke
Ian D Clarke
MTMizuhiko Terasaki
Mizuhiko Terasaki
VBVictoria E Bonn
Victoria E Bonn
CHCynthia Hawkins
Cynthia Hawkins
PDPeter B Dirks
Peter B Dirks

3 June 2012 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
DKDong-Anh Khuong-Quang
Dong-Anh Khuong-Quang
PBPawel Buczkowicz
Pawel Buczkowicz
PRPatricia Rakopoulos
Patricia Rakopoulos
XLXiao-Yang Liu
Xiao-Yang Liu
AFAdam M. Fontebasso
Adam M. Fontebasso
CHCynthia Hawkins
Cynthia Hawkins
Pediatric glioblastomas (GBM) including diffuse intrinsic pontine gliomas (DIPG) are devastating brain tumors with no effective therapy. Here, we investigated clinical and biological impacts of histone H3.3 mutations. Forty-two DIPGs were tested for H3.3 mutations. Wild-type versus mutated (K27M-H3.3) subgroups were compared for HIST1H3B, IDH, ATRX and TP53 mutations, copy number alterations and clinical outcome. K27M-H3.3 occurred in 71 %, TP53 mutations in 77 % and ATRX mutations in 9 % of DIPGs. ATRX mutations were more frequent in older children (p < 0.0001). No G34V/R-H3.3, IDH1/2 or H3.1 mutations were identified. K27M-H3.3 DIPGs showed specific copy number changes, including all gains/amplifications of PDGFRA and MYC/PVT1 loci. Notably, all long-term survivors were H3.3 wild type and this group of patients had better overall survival. K27M-H3.3 mutation defines clinically and biologically distinct subgroups and is prevalent in DIPG, which will impact future therapeutic trial design. K27M- and G34V-H3.3 have location-based incidence (brainstem/cortex) and potentially play distinct roles in pediatric GBM pathogenesis. K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival. Based on prognostic and therapeutic implications, our findings argue for H3.3-mutation testing at diagnosis, which should be rapidly integrated into the clinical decision-making algorithm, particularly in atypical DIPG.

6 April 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PBPawel Buczkowicz
Pawel Buczkowicz
CHChristine Hoeman
Christine Hoeman
PRPatricia Rakopoulos
Patricia Rakopoulos
SPSanja Pajovic
Sanja Pajovic
LLLouis Letourneau
Louis Letourneau
CHCynthia Hawkins
Cynthia Hawkins
Cynthia Hawkins, Oren Becher and colleagues report the identification of recurrent mutations in ACVR1 in 20% of diffuse intrinsic pontine gliomas. Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.

1 April 2020 in Cancer Cell
Verified
Journal Article
Closed access
SRScott Ryall
Scott Ryall
MZMichal Zapotocky
Michal Zapotocky
KFKohei Fukuoka
Kohei Fukuoka
LNLiana Nobre
Liana Nobre
ASAna Guerreiro Stucklin
Ana Guerreiro Stucklin
CHCynthia Hawkins
Cynthia Hawkins

12 March 2020 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
SRScott Ryall
Scott Ryall
UTUri Tabori
Uri Tabori
CHCynthia Hawkins
Cynthia Hawkins
Low grade gliomas are the most frequent brain tumors in children and encompass a spectrum of histologic entities which are currently assigned World Health Organisation grades I and II. They differ substantially from their adult counterparts in both their underlying genetic alterations and in the infrequency with which they transform to higher grade tumors. Nonetheless, children with low grade glioma are a therapeutic challenge due to the heterogeneity in their clinical behavior – in particular, those with incomplete surgical resection often suffer repeat progressions with resultant morbidity and, in some cases, mortality. The identification of up-regulation of the RAS–mitogen-activated protein kinase (RAS/MAPK) pathway as a near universal feature of these tumors has led to the development of targeted therapeutics aimed at improving responses while mitigating patient morbidity. Here, we review how molecular information can help to further define the entities which fall under the umbrella of pediatric-type low-grade glioma. In doing so we discuss the specific molecular drivers of pediatric low grade glioma and how to effectively test for them, review the newest therapeutic agents and their utility in treating this disease, and propose a risk-based stratification system that considers both clinical and molecular parameters to aid clinicians in making treatment decisions.

25 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAna S. Guerreiro Stucklin
Ana S. Guerreiro Stucklin
SRScott Ryall
Scott Ryall
KFKohei Fukuoka
Kohei Fukuoka
MZMichal Zapotocky
Michal Zapotocky
ALAlvaro Lassaletta
Alvaro Lassaletta
CHCynthia Hawkins
Cynthia Hawkins
Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinasesALK,ROS1,NTRKandMET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harborRAS/MAPKpathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.